Investing Center Preview – Manage your investments and watch your net worth grow.
UTHR:NASDAQ – Large Cap Stock (Drug Manufacturers - Specialty & Generic)
United Therapeutics Corp – UTHR Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
293.46 | 0.64 (+0.22%) | 233.28 - 417.82 | 225.3 thousand (Below Avg) |
Market data as of 4:00PM 04/23/25. Quotes are delayed by at least 15 min.
Overview - UTHR
Open | 295.62 |
---|---|
Previous Close | 292.82 |
Day's Range | 291.68 - 298.30 |
Market Cap | 13.2B |
Avg Volume (10 Day) | 435.1K |
Price/Earnings (Trailing 12 Mo.) | 11.5x |
Earnings Per Share (Trailing 12 Mo.) | 6.951 |
Dividend Yield | No Dividend |
One-Click Scorecard - UTHR


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Pass |
Converting sales to profits? | Pass |
Shareholder's money handled rationally? | Fail |
Increased shareholder value? | Fail |
Consistently increased owner earnings? | Fail |
Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Neutral |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Pass |
Stock is undervalued? | Fail |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - UTHR
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
Business Wire - Monday 04/21/2025 7:00 AM ET
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
Business Wire - Wednesday 04/16/2025 7:00 AM ET
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
Business Wire - Friday 04/04/2025 7:00 AM ET
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
Business Wire - Wednesday 04/02/2025 12:00 PM ET
Industry Position - UTHR
UTHR | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 23.63% | |
Net Income Growth (1yr) | 21.36% | |
Total Debt/Equity | 0.05 | |
LT Debt/Equity | -- | |
Earnings Yield | 8.67% | |
Price/Sales | 4.79 |